Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Principia Biopharma Inc

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Principia Biopharma Inc. to Sanofi

This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.

Sanofi Acquiring Principia Biopharma for $3.7 Billion

CVS Health

Flu season is nearly upon us. Here’s how you can get a flu shot without worrying about going into the doctor’s office.

Sanofi and CVS are building COVID-safe flu vaccination stations

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc.

PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm

TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.

Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma

Principia Biopharma Inc. (NASDAQ: PRNB) shares jumped to start out the week after it was announced that it would be acquired by Sanofi (NASDAQ: SNY).

What Sanofi Is Adding to Its Portfolio With This New Acquisition

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B

Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma.
The post Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts appeared first on Investor's Business Daily.

Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts

Sanofi S.A. (EPA: SAN) expressed plans of acquiring Principia Biopharma Inc.

Sanofi to acquire U.S. Principia Biopharma Inc. for £2.82 billion

Sanofi SA (NASDAQ: SNY) will acquire Principia Biopharma Inc (NASDAQ: PRNB) for $3.68 billion in cash, the two companies announced Monday.

Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B

French health care company Sanofi has agreed to buy U.S. company Principia Biopharma for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

French group Sanofi to buy U.S. firm Principia Biopharma for $3.7 billion

Sanofi to acquire Principia Biopharma

AstraZeneca

BioNTech SE

GlaxoSmithKline

Johnson & Johnson

Moderna

Novavax

Pfizer

The U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.

The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals stand

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Eli Lilly

Merck

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.

5 Biotech Stocks That Offer Long-Term Growth and Value

These Coronavirus Vaccine Makers Are Winning the Money Game So Far

The U.S. government is supporting development and manufacturing of the coronavirus vaccine in exchange for 100 million doses.

Sanofi and GlaxoSmithKline Snag a $2.1 Billion Contract for Their Coronavirus Vaccine

Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

This is the country’s biggest Covid-19 vaccine deal yet.

U.S. To Spend $2.1 Billion On GlaxoSmithKline-Sanofi Covid-19 Vaccine

The feds will give Sanofi and GlaxoSmithKline up to $2.1 billion to churn out a coronavirus vaccine in the Trump administration’s latest and largest bet on an experimental inoculation. More than half the award announced Friday will help the European drugmakers develop and test their vaccine, while the rest will be used to support manufacturing.

Feds pledge up to $2.1B to COVID-19 vaccine from Sanofi, GlaxoSmithKline

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

U.S. listed shares of Sanofi SNY, -0.64% gained 0.8% in premarket trading on Friday after it said the U.S.

Sanofi, GSK coronanvirus vaccine to get up to $2.1 billion from U.S. government

The agreement with Sanofi and GlaxoSmithKelin is the government's second in less than two weeks for 100 million doses of vaccine.

U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

Sanofi's (SNY) CEO Paul Hudson on Q2 2020 Results - Earnings Call Transcript

News for Sanofi Stock (SNY)